- 4-Week # shares sold: 3,000
- 12-Week # shares sold: 4,168
- 24-Week # shares sold: 8,609
Analysts were anticipating a loss of 14 cents a share on revenue of $7.26 billion.
Shares of this oil refiner could be poised for gains in the months ahead, thanks to pressure from an activist investor.
Horizon Pharma is a 'giant headache,' says Jim Cramer; Abbot Labs is OK long term.
Holiday-shortened week holds a feast of earnings reports, says Jim Cramer.